MedTrace Logo

MRCT Evaluating NCX 470 vs. Latanoprost in Subjects With Open-Angle Glaucoma or Ocular Hypertension

NCT04630808 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 696

Last updated 2025-09-08

No results posted yet for this study

Summary

The objective of this clinical study is to evaluate the safety and efficacy of NCX 470 Ophthalmic Solution in lowering intraocular pressure (IOP) in subjecs with ocular hypertension or open-angle glaucoma. Subjects will be randomized in a 1:1 ratio to NCX 470 0.1% or to latanoprost 0.005% to be administered to both eyes once daily in the evening for up to 12 months.

Conditions

Interventions

DRUG

NCX 470 0.1%

NCX 470 Ophthalmic Solution, 0.1%

DRUG

Latanoprost 0.005%

Latanoprost Ophthalmic Solution, 0.005%

Sponsors & Collaborators

  • Nicox Ophthalmics, Inc.

    lead INDUSTRY

Principal Investigators

  • Nicox Ophthalmics · Nicox Ophthalmics, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
84 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-11-09
Primary Completion
2025-04-11
Completion
2025-06-25
FDA Drug
Yes

Countries

  • United States
  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04630808 on ClinicalTrials.gov